Articles dans des revues avec comité de lecture (368)
82.
Muylle, K., Flamen, P., Vugts, D., Guiot, T., Ghanem, G. E., Meuleman, N., Bourgeois, P., Vanderlinden, B., van Dongen, G. A. M. S., Everaert, H., Vaes, M., & Bron, D. (2015). Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+ B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab. European journal of nuclear medicine and molecular imaging, 42(8), 1304-1314. doi:10.1007/s00259-015-3025-683.
Busser, H., Najar, M., Raicevic, G., Pieters, K., Velez Pombo, R., Philippart, P., Meuleman, N., Bron, D., & Lagneaux, L. (2015). Isolation and characterization of human mesenchymal stromal cells subpopulations: comparison of bone marrow and adipose tissue. Stem cells and development. doi:10.1089/scd.2015.017284.
Andre, T., Najar, M., Stamatopoulos, B., Pieters, K., Pradier, O., Bron, D., Meuleman, N., & Lagneaux, L. (2015). Immune impairments in multiple myeloma bone marrow mesenchymal stromal cells. Cancer immunology and immunotherapy, 64(2), 213-224. doi:10.1007/s00262-014-1623-y85.
Dubruille, S., Libert, Y., Merckaert, I., Reynaert, C., Vandenbossche, S., Roos, M., Bron, D., & Razavi, D. (2015). The prevalence and implications of elderly inpatients' desire for a formal psychological help at the start of cancer treatment. Psycho-oncology. doi:10.1002/pon.363686.
Stamatopoulos, B., Van Damme, M., Crompot, E., Dessars, B., El Housni, H., Mineur, P., Meuleman, N., Bron, D., & Lagneaux, L. (2015). Opposite prognostic significance of cellular and serum circulating microRNA-150 in Chronic Lymphocytic Leukemia patients. Molecular medicine. doi:10.2119/molmed.2014.0021488.
Crompot, E., Van Damme, M., Duvillier, H., Pieters, K., Vermeesch, M., Perez-Morga, D., Meuleman, N., Mineur, P., Bron, D., Lagneaux, L., & Stamatopoulos, B. (2015). Avoiding false positive antigen detection by flow cytometry on blood cell derived microparticles: the importance of an appropriate negative control. PloS one, 10(5), e0127209. doi:10.1371/journal.pone.012720989.
Czuczman, M. M., Fowler, N., Kahanic, S., Forero, A., Davis, G., Munteanu, M., Van Den Neste, E., Offner, F., Bron, D., & Quick, D. (2015). Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin’s lymphoma. Annals of hematology, 94(4), 633-641. doi:10.1007/s00277-014-2269-890.
Claes, G., Bron, D., Maerevoet, M., Benghiat, F., De Wilde, V., Bailly, B., Istaces, N., Brauner, J., Pradier, O., & Meuleman, N. (2015). P1.14 MONOCLONAL B-CELL LYMPHOCYTOSIS (MBL): RESULTS OF A ROUTINE SCREENING IN A GENERAL HOSPITAL. Belgian Journal of Hematology, 18.91.
Devos, T., Zachée, P., Bron, D., Noens, L., Droogenbroeck, J. V., Mineur, P., Beguin, Y., Berneman, Z., Benghiat, F., Kentos, A., Chatelain, C., Demuynck, H., Lemmens, J., Eygen, K. V., Theunissen, K., Trullemans, F., Pierre, P., Pluymers, W., & Knoops, L. (2014). Myelofibrosis patients in Belgium: disease characteristics. Acta Clinica Belgica (English ed. Printed), 2295333714Y0000000097. doi:10.1179/2295333714Y.000000009792.
Awan, F. F., Bron, D., et al. (2014). A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia. British journal of haematology, 167(4), 466-477. doi:10.1111/bjh.1306193.
Najar, M., Raicevic, G., Fayyad Kazan, H., De Bruyn, C., Bron, D., Toungouz Nevessignsky, M., & Lagneaux, L. (2014). Bone Marrow Mesenchymal Stromal Cells Induce Proliferative, Cytokinic and Molecular Changes During the T Cell Response: The Importance of the IL-10/CD210 Axis. Stem cell reviews. doi:10.1007/s12015-014-9567-3